

LETTER - THERAPY

Upadacitinib treatment of refractory livedoid vasculopathy: a case report and literature review[☆]



Dear Editor,

Livedoid vasculopathy (LV) is a rare, chronic, recurrent vascular disease that manifests as erythema, purpuric macules, painful ulcers, livedo reticularis, atrophic porcelain-white scars of the lower extremities, typically in ankles and feet. Although the pathophysiological process is not yet fully elucidated, thrombosis of the dermal vessels appears to be a key event.¹ The conventional therapies consist of anticoagulants, antiplatelets, corticosteroids, immunosuppressive agents, thrombolytics,² etc. However, patients commonly encounter disease relapse. Upadacitinib, a relatively new JAK1 inhibitor, has never been reported to be used in treating LV in the retrieved literature. Herein, we report a case of refractory LV resistant to conventional therapy which exhibited great efficacy following treatment with Upadacitinib.

A 30-year-old female presented with over 5-year history of painful, ulcerative lesions of the feet and ankles. Physical examination showed multiple purpura maculae, painful ulcerations with small, dilated blood vessels, as well as sporadic porcelain-white scars (Fig. 1). Laboratory investigations were found with positive anti-cardiolipin antibody, and helped us rule out other LV-associated systemic disorders. A skin biopsy revealed ulceration formation, vascular dilation, swollen vessel walls with fibrinoid necrosis, erythrocyte exosmosis, as well as infiltration of perivascular lymphocytes and neutrophils (Fig. 2). The examination findings and clinical manifestations were strongly consistent with the diagnosis of LV. Although the patient was previously prescribed rivaroxaban, aspirin, mycophenolate mofetil, and oral corticosteroids (prednisone 30 mg once daily), she was still confronted with disease relapse. We initiated Upadacitinib at a daily dose of 15 mg orally, along with topical ointment, hirudoid (mucopolysaccharide polysulfate cream). The patient manifested significant improvement in erythema and pain within 10-days, and achieved nearly complete resolution of ulceration and remained only post-inflammatory hyperpigmentation within 6-weeks (Fig. 3). No




Fig. 1 Physical examination showed multiple purpura macula, painful ulcerations with small dilated blood vessels as well as sporadic porcelain-white scars.

[☆] Study conducted at the Department of Dermatology, Zhongshan Second People's Hospital, Zhongshan City, Guangdong Province, China.




Fig. 2 Pathological and immunohistochemical specimens. (A) Low-power view showed ulceration formation, increased vascular proliferation and dilation (Hematoxylin & eosin, $\times 50$). (B) The infiltration of perivascular lymphocytes and swollen vessel walls with fibrinoid necrosis, erythrocyte exosmosis (original magnification: $\times 400$).




Fig. 3 After 6-weeks of treatment with Upadacitinib, the patient manifested significant improvement in erythema and pain, achieved nearly complete resolution of ulceration and remained only hyperpigmentation.

adverse events were observed during the 20-week follow-up. For clinical assessment, the expected time for Upadacitinib maintenance is 6-months, so as to reduce the recurrence of the patient.

The Janus Kinase (JAK) and Signal Transduction Transcription Activator (STAT) signal transduction pathways interplay with a wide range of immunocytes and over 50 cytokines. It was reported JAK-STAT pathways have enhanced activity in vascular endothelial cells;³ moreover, JAK signaling could significantly affect inflammation, coagulation, and thrombosis formation.⁴ The overactivation of JAK/STAT pathways induces immune imbalance and vascular damage.

LV is a thrombo-occlusive vascular disorder, which on histopathology manifests as hyaline thrombosis, fibrin deposits in vessel walls, along with perivascular focal lymphocyte infiltration. As described previously, it is still difficult to treat and prone to relapse. Existing experience suggests that steroids were suggested to be effective even as a monotherapy, and the traditional anti-inflammatory drugs could successfully improve the clinical outcomes. Concurrently, employing colchicine and prednisolone as monotherapy could exhibit higher efficacy than using pentoxifylline and aspirin alone in LV patients, indicating an

indispensable role of inflammation in LV pathogenesis.⁵ Given its pathophysiology, JAK inhibitors should theoretically play an important role in preventing the flares and recurrence of LV.

Previous small-scale retrospective studies and case reports have shown considerable efficacy when utilizing JAK inhibitors in LV treatment,^{5,6} as summarized in Table 1. Han et al. observed 8 patients who received 2 mg/day of baricitinib for treating refractory LV, and found that all enrolled patients experienced a significant regression with a mean remission time of 7.75-weeks. Similarly, in the case series of Song et al., 3 patients with LV were prescribed 2 mg/day of baricitinib. One patient obtained darkening and reduced erythema by month-6, and the other two obtained complete ulcer healing, respectively, by month-1 and month-2. Regarding other JAK inhibitors, Chen et al. reported the rapid improvement in a 31-year-old female developing LV after using abrocitinib 100mg once daily. In addition, Jia et al. administered tofacitinib 5mg twice per day on a 17-year-old male with refractory LV, the ulcers were completely healed within a month with no recurrence during the 56-week follow-up. The aforementioned clinical prac-

Table 1 Overview of JAK inhibitors as a novel treatment for livedoid vasculopathy.

Study	No.	Sex	Age	Duration of Disease	Previous Treatment	Treatment	Outcome	Adverse event	Follow-up time
Han et al.	8	5F/3M	8~36	7~120 months	Diverse therapies (Aspirin, corticosteroid; thalidomide; tripterygium glycosides; rivaroxaban; enoxaparin; compound glycyrrhizin; Chinese traditional anti-inflammatory drugs)	Baricitinib 2 mg/day	All experienced significant regression; remission times ranging from 3- to 13-weeks, with a mean remission time of 7.75 ± 3.45 weeks	None	11–28 weeks
Chen et al.	1	1F	31	2-years	NR	Abrocitinib 100 mg/day	Complete remission was achieved after 6-weeks, with only post-inflammatory hyperpigmentation remaining	None	12-weeks
Song et al.	3	1F/2M	8–26	6~72 months	Diverse therapies (Prednisone, rivaroxaban, thalidomide, aspirin)	Baricitinib 2 mg/day	Patient 1: reduced erythema by month-6; Patient 2/3: Complete healing of ulcer by month 1/2	None	
Jia et al.	1	1M	17	3-years	Colchicine, thalidomide, dipyridamole, rivaroxaban and aspirin	Tofacitinib 5 mg twice daily	Complete healing of ulcer by month-1	None	56-weeks

JAK, Janus Kinase; M, Male; F, Female; NR, Not Report.

tice suggests that JAK inhibitors are promising therapeutic options to treat LV. Upadacitinib is an oral, small-molecule JAK1 inhibitor that has been approved for multiple inflammatory diseases in dermatology. There are no reports to date for its application on LV. In our case, using 15 mg/day of Upadacitinib, the patient achieved great improvement within 10-days and the ulceration completely healed within 6-weeks.

To our knowledge, this is the first report in which Upadacitinib was utilized to treat LV. Further studies should be conducted to confirm its efficacy and long-term safety.

ORCID IDs

Xiaoqian Liang: 0000-0001-8806-8533; Xueyi Huang: 0000-0002-3114-589X

Authors' contributions

Jiecheng Zheng: The study concept and design; data collection, or analysis and interpretation of data; Writing of

the manuscript or critical review of important intellectual content; Data collection, analysis and interpretation.

Xiaoqian Liang: The study concept and design; data collection, or analysis and interpretation of data; Writing of the manuscript or critical review of important intellectual content; Data collection, analysis and interpretation.

Xueyi Huang: Data collection, or analysis and interpretation of data.

Jia Liao: Effective participation in the research guidance; Final approval of the final version of the manuscript.

Financial support

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Research data availability

Does not apply.

Conflicts of interest

None declared.

Editor

Luciana P. Fernandes Abbade

References

1. Lacerda PN, Garcia LC, Mazeto IFDS, Miot HA, Abbade LPF. Livedoid vasculopathy, calciphylaxis, and Martorell's hypertensive ulcer: update on ischemic ulcers due to impaired microcirculation of the lower limbs. *An Bras Dermatol*. 2025;100:215–27.
2. Micieli R, Alavi A. Treatment for livedoid vasculopathy: A Systematic Review. *JAMA Dermatol*. 2018;154:193–202.
3. Ebata A, Ogawa-Momohara M, Fukaura R, Yamashita Y, Koizumi H, Takeichi T, et al. Increased Janus kinase activation in cutaneous vasculitis. *J Am Acad Dermatol*. 2024;90:627–9.
4. Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. *Cells*. 2019;8:e854.
5. Han Y, Tu P. Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy. *Front Immunol*. 2022;13:1008392.
6. Song X, Tu P. Treatment of livedoid vasculopathy with Baricitinib. *JAMA Dermatol*. 2022;158:587–9.

Jiecheng Zheng ¹, Xiaoqian Liang¹, Xueyi Huang, Jia Liao ^{*}

Department of Dermatology, Zhongshan Second People's Hospital, Zhongshan City, Guangdong Province, China

^{*} Corresponding author.

E-mail: liaoqia1014@163.com (J. Liao).

¹ The authors have contributed equally to this work and share first authorship.

Received 6 April 2025; accepted 27 May 2025

Available online 4 November 2025